---
title: "FDA approves Isembyld for spinal muscular atrophy — first therapy targeting muscle loss"
id: "stat-news-0-stat-scholar-rock-wins-fda-approval-for-first-drug-to-target-sma-muscle-loss"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-stat-scholar-rock-wins-fda-approval-for-first-drug-to-target-sma-muscle-loss"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/09/11/scholar-rock-spinal-muscular-atrophy-isembyld-clinical-trial-fda-approval/?utm_campaign=rss"
published_at: "2026-09-11T23:30:21.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# FDA approves Isembyld for spinal muscular atrophy — first therapy targeting muscle loss
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-stat-scholar-rock-wins-fda-approval-for-first-drug-to-target-sma-muscle-loss
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/09/11/scholar-rock-spinal-muscular-atrophy-isembyld-clinical-trial-fda-approval/?utm_campaign=rss)
- **Published At:** 2026-09-11T23:30:21.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The FDA has approved **Isembyld** (apitegromab) as the first therapy specifically targeting the loss of muscle in people with **spinal muscular atrophy (SMA)**. - Approval covers adults and children aged 2 years and older who are already receiving therapies that target **SMN2**, the gene important for motor neurons that control movement. - A late-stage clinical trial reported that, when added to an SMN2-targeting therapy, Isembyld produced statistically significant improvements in **motor skills** in young patients after one year; patients on placebo declined over the same period. - Scholar Rock’s CEO, David Hallal, described the approval as a therapeutic breakthrough and emphasized the company’s achievement in **myostatin inhibition**, a strategy that had been challenging for the industry. - The STAT article reporting the approval is a STAT+ exclusive; the published piece is by Jonathan Wosen and dated Sept. 11, 2026. - The source article does not report additional trial details such as patient numbers, exact effect sizes, safety and adverse-event data, dosing regimen, or regulatory review timeline; those specifics were not provided in the source. - The approval is positioned as complementing existing **SMN2-targeting** therapies rather than replacing them, indicating Isembyld is intended as add-on therapy for motor improvement in treated patients. - STAT’s coverage notes the historical difficulty of translating **myostatin inhibition** into clinical benefit for SMA and frames Isembyld’s approval as the first regulatory success for that approach. - Further clinical, safety, and access details were not included in the STAT source and would require consultation of the FDA label or company disclosures for comprehensive information.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/09/11/scholar-rock-spinal-muscular-atrophy-isembyld-clinical-trial-fda-approval/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/09/11/scholar-rock-spinal-muscular-atrophy-isembyld-clinical-trial-fda-approval/?utm_campaign=rss) [Congress](https://www.statnews.com/topic/congress/) [neurology](https://www.statnews.com/topic/neurology/) [Cancer](https://www.statnews.com/topic/cancer/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)[Biotech](https://www.statnews.com/category/biotech/) # Scholar Rock wins FDA approval for first drug to target SMA muscle loss ## Late-stage trial finds therapy improves young patients’ motor skills * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/09/11/scholar-rock-spinal-muscular-atrophy-isembyld-clinical-trial-fda-approval/?utm_campaign=rss) ![Two syringes against a light blue background, facing different directions. -- first opinion coverage from STAT](https://www.statnews.com/wp-content/uploads/2025/05/AdobeStock_406860486-645x645.jpeg) Adobe ![](https://www.statnews.com/wp-content/uploads/2022/01/jonathan-w-avatar-round-80x80.png) By [Jonathan Wosen](https://www.statnews.com/staff/jonathan-wosen/) Sept. 11, 2026 West Coast Biotech & Life Sciences Reporter ![](https://www.statnews.com/wp-content/uploads/2022/01/jonathan-w-avatar-round-80x80.png) [Jonathan Wosen](https://www.statnews.com/staff/jonathan-wosen/) 1. [](https://www.linkedin.com/in/jonathan-wosen-phd-b69172147/ "Linkedin") 2. [](https://x.com/JonathanWosen "X") jonathan.wosen@statnews.com Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Scholar Rock on Friday received Food and Drug Administration approval for the first-ever therapy that targets the loss of muscle in spinal muscle atrophy, raising hopes that patients with the rare neurological disorder might have a better chance of moving and walking independently. The FDA approved the drug, Isembyld, for use in adults and children 2 years and older who are currently receiving SMA therapies that target SMN2, a key gene for neurons that control movement. A [late-stage](https://www.statnews.com/2024/10/07/scholar-rock-drug-for-spinal-muscular-atrophy-succeeds-in-late-stage-study/) clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year, while those in a placebo group declined, a difference that was statistically significant. Advertisement “Today’s FDA approval of Isembyld marks a defining moment for the SMA community,” said David Hallal, CEO of Scholar Rock, in a press [release](https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-announces-fda-approval-isembyldtm-apitegromab-mstn). “After decades of failed industry-wide efforts to unlock the potential of myostatin inhibition, Scholar Rock has delivered a therapeutic breakthrough.” STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [FDA](https://www.statnews.com/topic/fda/), [Pharmaceuticals](https://www.statnews.com/topic/pharmaceuticals/), [research](https://www.statnews.com/topic/research/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2022/01/jonathan-w-avatar-round-80x80.png) [Jonathan Wosen](https://www.statnews.com/staff/jonathan-wosen/) 1. [](https://x.com/JonathanWosen "X") 2. 3. [](https://www.linkedin.com/in/jonathan-wosen-phd-b69172147/ "Linkedin") West Coast Biotech & Life Sciences Reporter 1. [](https://x.com/JonathanWosen "X") 2. 3. [](https://www.linkedin.com/in/jonathan-wosen-phd-b69172147/ "Linkedin") Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2024/03/Biotech-Scorecard-Logo-NoSTAT-640x290.png) ### STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/09/GettyImages-2289339879-80x80.jpg) [John Fetterman’s post-stroke, politically problematic behaviors offer lessons about brain health on Capitol Hill](https://www.statnews.com/2026/09/10/john-fetterman-post-stroke-behavior-experts-see-neurological-changes/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/09/Screenshot-2026-09-10-at-11.16.19-AM-e1789064257681-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field](https://www.statnews.com/2026/09/11/novartis-novo-nordisk-cardiovascular-drug-trials-fallout/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/09/AdobeStock_1085203947_Editorial_Use_Only-80x80.jpeg) [Medicaid will let states use ‘tiers’ to determine medical frailty ](https://www.statnews.com/2026/09/11/medicaid-work-requirements-new-tier-system-define-medical-frailty/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/09/Solano-Family-80x80.jpg) [A breakthrough pancreatic cancer drug won approval. They still struggle to access it](https://www.statnews.com/2026/09/08/pancreatic-cancer-patients-caught-beween-fda-drug-approval-insurance-coverage/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/09/AP010911013885-80x80.jpg) [I’m a thoracic surgeon in New York City. For many of my patients, Sept. 11 is still not over](https://www.statnews.com/2026/09/11/sept-11-25th-anniversary-ground-zero-exposure-cancer-moment-of-silence/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/924_Samsung_VirtualEvent_Wordpress_FeaturedImage-80x80.jpg) Biosimilars: Have We Reached an Inflection Point? Virtual Sep 24 ](https://www.statnews.com/event/biosimilars-what-is-next-virtual-event-sept-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/09/Lindsay_Clancy_Trial_8_1_1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Lindsay Clancy case exposes dangers of fragmented U.S. health system, experts say](https://www.statnews.com/2026/09/04/lindsay-clancy-health-care-silos-postpartum-care-failures/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/01/heart-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation](https://www.statnews.com/2026/09/07/novo-nordisk-heart-studies-inflammation-ziltivekimab/) 3. ![](https://www.statnews.com/wp-content/uploads/2018/10/STAT_Novartis02-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Novartis’ experimental cardiovascular drug fails a pivotal study](https://www.statnews.com/2026/09/04/novartis-therapy-pelacarsen-fails-cardiovascular-trial/) 4. ![](https://www.statnews.com/wp-content/uploads/2023/04/AdobeStock_521699065_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA warns an API supplier about residue on walls, a corroded product line, and open-toed sandals](https://www.statnews.com/pharmalot/2026/09/08/fda-warns-api-supplier-residue-corroded-production-line-sandals/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/09/C0400970-Smoker_s_lungs_and_emphysema_3D_CT_scan-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies](https://www.statnews.com/2026/09/08/astrazeneca-tozorakimab-copd-exacerbations-titania-oberon/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout September 11, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Cancer drug shortages keep disrupting patient care ](https://www.statnews.com/2026/09/11/biotech-news-cancer-drug-shortages-keep-disrupting-patient-care/) By [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout LOUD The Readout LOUD September 11, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field ](https://www.statnews.com/2026/09/11/novartis-novo-nordisk-cardiovascular-drug-trials-fallout/) By [Allison DeAngelis](https://www.statnews.com/staff/allison-deangelis/) and [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout September 10, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: FDA expands Bayer lung cancer drug approval ](https://www.statnews.com/2026/09/10/biotech-news-fda-expands-bayer-lung-cancer-drug-approval/) By [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard September 10, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon ](https://www.statnews.com/2026/09/10/roivant-biotech-dealmaking-mosliciguat-origins/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard September 10, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: What to expect from UniQure’s upcoming Huntington’s gene therapy readout ](https://www.statnews.com/2026/09/10/uniqure-huntingtons-gene-therapy-trial-readout/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field ](https://www.statnews.com/2026/09/11/novartis-novo-nordisk-cardiovascular-drug-trials-fallout/) By [Allison DeAngelis](https://www.statnews.com/staff/allison-deangelis/) and [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Lindsay Clancy case exposes dangers of fragmented U.S. health system, experts say ](ht
## Related Clinical Research

- [Medicare expands ACCESS pilot to cover more chronic conditions and lists 39 providers](https://medichelpline.com/clinical-feed/stat-news-1-stat-medicare-to-expand-its-pilot-that-pays-for-technology-to-manage-chronic.md)
- [Many physicians still accept pharma freebies and rely on sales reps, analysis finds](https://medichelpline.com/clinical-feed/stat-news-0-stat-the-gifts-from-pharma-companies-that-keep-on-giving.md)
- [Waist circumference predicts mortality more than BMI in adults 65+: study findings](https://medichelpline.com/clinical-feed/medical-news-today-0-bmi-vs-waist-size-study-finds-belly-fat-matters-more-than-weight-for-death-risk.md)
- [Keto Diet Shows Superior Metabolic Benefits Over Mediterranean and Low-Fat Diets](https://medichelpline.com/clinical-feed/medical-news-today-1-keto-diet-may-have-metabolic-advantages-over-mediterranean-low-fat-diets.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.